IP Library › Granted Patent US 10,342,882
Granted Patent B2
US 10,342,882 · App. 15/265,158 · Granted Jul 9, 2019

TCO conjugates and methods for delivery of therapeutic agents

Inventors: Jose Manuel Mejia Oneto (Oakland, CA); Maksim Royzen (Albany, NY)
Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
A61K51/065A61K31/43A61K31/7076A61K38/12A61K38/14A61K47/54A61K47/542A61K47/545A61K47/61A61K47/665A61K47/6903A61K49/0041A61K49/0043A61K49/0052A61K49/0054A61K49/0073A61K51/0482A61K51/0495A61K51/1213C07D257/08C07D311/82C07D499/74C07H7/02C07H15/24C07H19/167C07H19/213
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,342,882
App. No.
15/265,158
Granted
Jul 9, 2019
Kind
B2
Abstract

The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.

Claims (25)

1. A bioactive composition comprising:

a therapeutic agent other than doxorubicin, vancomycin, and paclitaxel;

a binding agent comprising a trans-cyclooctene; and

a linker comprising from about 1 to about 10 linking atoms, covalently linking the binding agent to the therapeutic agent.

2. The composition of claim 1 , wherein the linker comprises the structure of:

3. The composition of claim 1 , wherein the binding agent and the linker together have the structure selected from the group consisting of

4. The bioactive composition of claim 1 , wherein the therapeutic agent is daptomycin, irinotecan, SN-38, amoxicillin, cyclic AMP, doxycyclin, amphotericin, ixabepilone, podophyllotoxin, patupilone, or rapamycin.

5. The bioactive composition of claim 4 , wherein the therapeutic agent is daptomycin.

6. The bioactive composition of claim 4 , wherein the therapeutic agent is irinotecan.

7. The bioactive composition of claim 4 , wherein the therapeutic agent is SN-38.

8. The bioactive composition of claim 4 , wherein the therapeutic agent is amoxicillin.

9. The bioactive composition of claim 4 , wherein the therapeutic agent is cyclic AMP.

10. The bioactive composition of claim 4 , wherein the therapeutic agent is doxycyclin.

11. The bioactive composition of claim 4 , wherein the therapeutic agent is amphotericin.

12. A bioactive composition comprising a therapeutic agent other than doxorubicin, wherein the therapeutic agent is linked by a covalent bond to a structure

13. The bioactive composition of claim 12 , wherein the therapeutic agent is vancomycin, paclitaxel, daptomycin, etoposide, irinotecan, SN-38, amoxicillin, cyclic AMP, doxycyclin, amphotericin, ixabepilone, podophyllotoxin, patupilone, or rapamycin.

14. The bioactive composition of claim 13 , wherein the therapeutic agent is vancomycin.

15. The bioactive composition of claim 13 , wherein the therapeutic agent is paclitaxel.

16. The bioactive composition of claim 13 , wherein the therapeutic agent is daptomycin.

17. The bioactive composition of claim 13 , wherein the therapeutic agent is SN-38.

18. A bioactive composition comprising:

a diagnostic agent;

a binding agent comprising a trans-cyclooctene; and

a linker comprising from about 1 to about 10 linking atoms, covalently linking the binding agent to the diagnostic agent.

19. The bioactive composition of claim 18 , wherein the diagnostic agent is an optical probe.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2017
From: ROYZEN, MAKSIM
To: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Reel/Frame 041784/0840 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2017
From: MEJIA ONETO, JOSE MANUEL
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 041275/0361 →
Continuity (5)
Continuation PCTUS2015020718 · Mar 16, 2015
Provisional Application 62083022 · Nov 21, 2014
Provisional Application 62013994 · Jun 18, 2014
Provisional Application 61953294 · Mar 14, 2014
Related Publication 20170087258A1 · Mar 30, 2017
Cited By (6)
US 12,194,100 US 12,257,326 US 12,296,017 US 12,527,874 US 12,589,162 US 12,611,461